世界の腎臓がん用薬剤市場予測2021-2027:血管新生阻害剤、mTOR阻害剤、モノクローナル抗体、サイトカイン免疫療法(IL-2)

Market Monitor Globalが発行した調査報告書(MMG21DC17518)
◆英語タイトル:Kidney Cancer Drugs Market - Global Outlook and Forecast 2021-2027
◆商品コード:MMG21DC17518
◆発行会社(リサーチ会社):Market Monitor Global
◆発行日:2021年12月(※2024年版があります。お問い合わせください。)
◆ページ数:113
◆レポート形式:英語 / PDF
◆納品方法:Eメール(受注後2-3営業日)
◆調査対象地域:グローバル、北米、アメリカ、ヨーロッパ、アジア、日本、中国、東南アジア、インド、南米、中東・アフリカなど
◆産業分野:医薬品
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD3,250 ⇒換算¥481,000見積依頼/購入/質問フォーム
Multi User(20名様閲覧用)USD4,225 ⇒換算¥625,300見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はMarket Monitor Global社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。Market Monitor Global社の概要及び新刊レポートはこちらでご確認いただけます。

Market Monitor Global社が発行した本調査レポートは、世界の腎臓がん用薬剤市場について調査し取りまとめました。腎臓がん用薬剤の世界市場規模(2016年-2027年)、市場予測、企業別市場シェア、種類別分析(血管新生阻害剤、mTOR阻害剤、モノクローナル抗体、サイトカイン免疫療法(IL-2))、用途別分析(腎細胞癌(RCC)、移行上皮癌(TCC))、地域別分析(北米、アメリカ、カナダ、メキシコ、ヨーロッパ、ドイツ、フランス、イギリス、アジア、中国、日本、韓国、東南アジア、インド、南米、ブラジル、中東、アフリカなど)、関連メーカーの概要、市場動向・機会・成長・阻害要因、サプライチェーンなどの情報をお届けいたします。
・世界の腎臓がん用薬剤市場規模2021年vs2027年
・世界の腎臓がん用薬剤市場:売上予測2016年-2027年
・主要企業別の腎臓がん用薬剤売上・市場シェア・価格
・腎臓がん用薬剤の種類別市場規模:血管新生阻害剤、mTOR阻害剤、モノクローナル抗体、サイトカイン免疫療法(IL-2)
・腎臓がん用薬剤の用途別市場規模:腎細胞癌(RCC)、移行上皮癌(TCC)
・地域別市場規模
・腎臓がん用薬剤の北米市場:アメリカ市場、カナダ市場、メキシコ市場
・腎臓がん用薬剤のヨーロッパ市場:ドイツ市場、フランス市場、イギリス市場など
・腎臓がん用薬剤のアジア市場:中国市場、日本市場、韓国市場、東南アジア市場など
・腎臓がん用薬剤の南米市場:ブラジル市場、アルゼンチン市場など
・腎臓がん用薬剤の中東・アフリカ市場:トルコ市場、サウジアラビア市場、UAE市場など
・主要メーカー及びブランド概要:Bayer、Roche、GlaxoSmithKline、Novartis、Pfizer、Abbott Laboratories、Active Biotech、Amgen、Argos Therapeutics、ArQule、AVEO Pharmaceuticals、Bionomics、Bristol-Myers Squibb、Cerulean Pharma、Exelixis、Genentech、immatics biotechnologies、Immunicum、Ono Pharmaceutical、Onyx Therapeutics、Oxford BioMedica、Prometheus Laboratories、Seattle Genetics、Taiwan Liposome、Tracon Pharmaceuticals、Wilex
・世界の腎臓がん用薬剤の生産能力2016年-2027年
・市場動向・機会・成長・阻害要因分析
・腎臓がん用薬剤のサプライチェーン分析
・調査の結論
【レポートの概要】

This report contains market size and forecasts of Kidney Cancer Drugs in global, including the following market information:
Global Kidney Cancer Drugs Market Revenue, 2016-2021, 2022-2027, ($ millions)
Global Kidney Cancer Drugs Market Sales, 2016-2021, 2022-2027, (K Units)
Global top five Kidney Cancer Drugs companies in 2020 (%)
The global Kidney Cancer Drugs market was valued at 4085 million in 2020 and is projected to reach US$ 4800.1 million by 2027, at a CAGR of 4.1% during the forecast period.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Kidney Cancer Drugs manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Kidney Cancer Drugs Market, By Type, 2016-2021, 2022-2027 ($ Millions) & (K Units)
Global Kidney Cancer Drugs Market Segment Percentages, By Type, 2020 (%)
Angiogenesis Inhibitors
mTOR Inhibitors
Monoclonal Antibodies
Cytokine Immunotherapy (IL-2)

Global Kidney Cancer Drugs Market, By Application, 2016-2021, 2022-2027 ($ Millions) & (K Units)
Global Kidney Cancer Drugs Market Segment Percentages, By Application, 2020 (%)
Renal Cell Carcinoma (RCC)
Transitional Cell Carcinoma (TCC)

Global Kidney Cancer Drugs Market, By Region and Country, 2016-2021, 2022-2027 ($ Millions) & (K Units)
Global Kidney Cancer Drugs Market Segment Percentages, By Region and Country, 2020 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa

Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Kidney Cancer Drugs revenues in global market, 2016-2021 (Estimated), ($ millions)
Key companies Kidney Cancer Drugs revenues share in global market, 2020 (%)
Key companies Kidney Cancer Drugs sales in global market, 2016-2021 (Estimated), (K Units)
Key companies Kidney Cancer Drugs sales share in global market, 2020 (%)
Further, the report presents profiles of competitors in the market, key players include:
Bayer
Roche
GlaxoSmithKline
Novartis
Pfizer
Abbott Laboratories
Active Biotech
Amgen
Argos Therapeutics
ArQule
AVEO Pharmaceuticals
Bionomics
Bristol-Myers Squibb
Cerulean Pharma
Exelixis
Genentech
immatics biotechnologies
Immunicum
Ono Pharmaceutical
Onyx Therapeutics
Oxford BioMedica
Prometheus Laboratories
Seattle Genetics
Taiwan Liposome
Tracon Pharmaceuticals
Wilex

【レポートの目次】

1 Introduction to Research & Analysis Reports
1.1 Kidney Cancer Drugs Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Kidney Cancer Drugs Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Kidney Cancer Drugs Overall Market Size
2.1 Global Kidney Cancer Drugs Market Size: 2021 VS 2027
2.2 Global Kidney Cancer Drugs Revenue, Prospects & Forecasts: 2016-2027
2.3 Global Kidney Cancer Drugs Sales (Consumption): 2016-2027
3 Company Landscape
3.1 Top Kidney Cancer Drugs Players in Global Market
3.2 Top Global Kidney Cancer Drugs Companies Ranked by Revenue
3.3 Global Kidney Cancer Drugs Revenue by Companies
3.4 Global Kidney Cancer Drugs Sales by Companies
3.5 Global Kidney Cancer Drugs Price by Manufacturer (2016-2021)
3.6 Top 3 and Top 5 Kidney Cancer Drugs Companies in Global Market, by Revenue in 2020
3.7 Global Manufacturers Kidney Cancer Drugs Product Type
3.8 Tier 1, Tier 2 and Tier 3 Kidney Cancer Drugs Players in Global Market
3.8.1 List of Global Tier 1 Kidney Cancer Drugs Companies
3.8.2 List of Global Tier 2 and Tier 3 Kidney Cancer Drugs Companies
4 Sights by Product
4.1 Overview
4.1.1 By Type – Global Kidney Cancer Drugs Market Size Markets, 2021 & 2027
4.1.2 Angiogenesis Inhibitors
4.1.3 mTOR Inhibitors
4.1.4 Monoclonal Antibodies
4.1.5 Cytokine Immunotherapy (IL-2)
4.2 By Type – Global Kidney Cancer Drugs Revenue & Forecasts
4.2.1 By Type – Global Kidney Cancer Drugs Revenue, 2016-2021
4.2.2 By Type – Global Kidney Cancer Drugs Revenue, 2022-2027
4.2.3 By Type – Global Kidney Cancer Drugs Revenue Market Share, 2016-2027
4.3 By Type – Global Kidney Cancer Drugs Sales & Forecasts
4.3.1 By Type – Global Kidney Cancer Drugs Sales, 2016-2021
4.3.2 By Type – Global Kidney Cancer Drugs Sales, 2022-2027
4.3.3 By Type – Global Kidney Cancer Drugs Sales Market Share, 2016-2027
4.4 By Type – Global Kidney Cancer Drugs Price (Manufacturers Selling Prices), 2016-2027
5 Sights by Application
5.1 Overview
5.1.1 By Application – Global Kidney Cancer Drugs Market Size, 2021 & 2027
5.1.2 Renal Cell Carcinoma (RCC)
5.1.3 Transitional Cell Carcinoma (TCC)
5.2 By Application – Global Kidney Cancer Drugs Revenue & Forecasts
5.2.1 By Application – Global Kidney Cancer Drugs Revenue, 2016-2021
5.2.2 By Application – Global Kidney Cancer Drugs Revenue, 2022-2027
5.2.3 By Application – Global Kidney Cancer Drugs Revenue Market Share, 2016-2027
5.3 By Application – Global Kidney Cancer Drugs Sales & Forecasts
5.3.1 By Application – Global Kidney Cancer Drugs Sales, 2016-2021
5.3.2 By Application – Global Kidney Cancer Drugs Sales, 2022-2027
5.3.3 By Application – Global Kidney Cancer Drugs Sales Market Share, 2016-2027
5.4 By Application – Global Kidney Cancer Drugs Price (Manufacturers Selling Prices), 2016-2027
6 Sights by Region
6.1 By Region – Global Kidney Cancer Drugs Market Size, 2021 & 2027
6.2 By Region – Global Kidney Cancer Drugs Revenue & Forecasts
6.2.1 By Region – Global Kidney Cancer Drugs Revenue, 2016-2021
6.2.2 By Region – Global Kidney Cancer Drugs Revenue, 2022-2027
6.2.3 By Region – Global Kidney Cancer Drugs Revenue Market Share, 2016-2027
6.3 By Region – Global Kidney Cancer Drugs Sales & Forecasts
6.3.1 By Region – Global Kidney Cancer Drugs Sales, 2016-2021
6.3.2 By Region – Global Kidney Cancer Drugs Sales, 2022-2027
6.3.3 By Region – Global Kidney Cancer Drugs Sales Market Share, 2016-2027
6.4 North America
6.4.1 By Country – North America Kidney Cancer Drugs Revenue, 2016-2027
6.4.2 By Country – North America Kidney Cancer Drugs Sales, 2016-2027
6.4.3 US Kidney Cancer Drugs Market Size, 2016-2027
6.4.4 Canada Kidney Cancer Drugs Market Size, 2016-2027
6.4.5 Mexico Kidney Cancer Drugs Market Size, 2016-2027
6.5 Europe
6.5.1 By Country – Europe Kidney Cancer Drugs Revenue, 2016-2027
6.5.2 By Country – Europe Kidney Cancer Drugs Sales, 2016-2027
6.5.3 Germany Kidney Cancer Drugs Market Size, 2016-2027
6.5.4 France Kidney Cancer Drugs Market Size, 2016-2027
6.5.5 U.K. Kidney Cancer Drugs Market Size, 2016-2027
6.5.6 Italy Kidney Cancer Drugs Market Size, 2016-2027
6.5.7 Russia Kidney Cancer Drugs Market Size, 2016-2027
6.5.8 Nordic Countries Kidney Cancer Drugs Market Size, 2016-2027
6.5.9 Benelux Kidney Cancer Drugs Market Size, 2016-2027
6.6 Asia
6.6.1 By Region – Asia Kidney Cancer Drugs Revenue, 2016-2027
6.6.2 By Region – Asia Kidney Cancer Drugs Sales, 2016-2027
6.6.3 China Kidney Cancer Drugs Market Size, 2016-2027
6.6.4 Japan Kidney Cancer Drugs Market Size, 2016-2027
6.6.5 South Korea Kidney Cancer Drugs Market Size, 2016-2027
6.6.6 Southeast Asia Kidney Cancer Drugs Market Size, 2016-2027
6.6.7 India Kidney Cancer Drugs Market Size, 2016-2027
6.7 South America
6.7.1 By Country – South America Kidney Cancer Drugs Revenue, 2016-2027
6.7.2 By Country – South America Kidney Cancer Drugs Sales, 2016-2027
6.7.3 Brazil Kidney Cancer Drugs Market Size, 2016-2027
6.7.4 Argentina Kidney Cancer Drugs Market Size, 2016-2027
6.8 Middle East & Africa
6.8.1 By Country – Middle East & Africa Kidney Cancer Drugs Revenue, 2016-2027
6.8.2 By Country – Middle East & Africa Kidney Cancer Drugs Sales, 2016-2027
6.8.3 Turkey Kidney Cancer Drugs Market Size, 2016-2027
6.8.4 Israel Kidney Cancer Drugs Market Size, 2016-2027
6.8.5 Saudi Arabia Kidney Cancer Drugs Market Size, 2016-2027
6.8.6 UAE Kidney Cancer Drugs Market Size, 2016-2027
7 Manufacturers & Brands Profiles
7.1 Bayer
7.1.1 Bayer Corporate Summary
7.1.2 Bayer Business Overview
7.1.3 Bayer Kidney Cancer Drugs Major Product Offerings
7.1.4 Bayer Kidney Cancer Drugs Sales and Revenue in Global (2016-2021)
7.1.5 Bayer Key News
7.2 Roche
7.2.1 Roche Corporate Summary
7.2.2 Roche Business Overview
7.2.3 Roche Kidney Cancer Drugs Major Product Offerings
7.2.4 Roche Kidney Cancer Drugs Sales and Revenue in Global (2016-2021)
7.2.5 Roche Key News
7.3 GlaxoSmithKline
7.3.1 GlaxoSmithKline Corporate Summary
7.3.2 GlaxoSmithKline Business Overview
7.3.3 GlaxoSmithKline Kidney Cancer Drugs Major Product Offerings
7.3.4 GlaxoSmithKline Kidney Cancer Drugs Sales and Revenue in Global (2016-2021)
7.3.5 GlaxoSmithKline Key News
7.4 Novartis
7.4.1 Novartis Corporate Summary
7.4.2 Novartis Business Overview
7.4.3 Novartis Kidney Cancer Drugs Major Product Offerings
7.4.4 Novartis Kidney Cancer Drugs Sales and Revenue in Global (2016-2021)
7.4.5 Novartis Key News
7.5 Pfizer
7.5.1 Pfizer Corporate Summary
7.5.2 Pfizer Business Overview
7.5.3 Pfizer Kidney Cancer Drugs Major Product Offerings
7.5.4 Pfizer Kidney Cancer Drugs Sales and Revenue in Global (2016-2021)
7.5.5 Pfizer Key News
7.6 Abbott Laboratories
7.6.1 Abbott Laboratories Corporate Summary
7.6.2 Abbott Laboratories Business Overview
7.6.3 Abbott Laboratories Kidney Cancer Drugs Major Product Offerings
7.6.4 Abbott Laboratories Kidney Cancer Drugs Sales and Revenue in Global (2016-2021)
7.6.5 Abbott Laboratories Key News
7.7 Active Biotech
7.7.1 Active Biotech Corporate Summary
7.7.2 Active Biotech Business Overview
7.7.3 Active Biotech Kidney Cancer Drugs Major Product Offerings
7.4.4 Active Biotech Kidney Cancer Drugs Sales and Revenue in Global (2016-2021)
7.7.5 Active Biotech Key News
7.8 Amgen
7.8.1 Amgen Corporate Summary
7.8.2 Amgen Business Overview
7.8.3 Amgen Kidney Cancer Drugs Major Product Offerings
7.8.4 Amgen Kidney Cancer Drugs Sales and Revenue in Global (2016-2021)
7.8.5 Amgen Key News
7.9 Argos Therapeutics
7.9.1 Argos Therapeutics Corporate Summary
7.9.2 Argos Therapeutics Business Overview
7.9.3 Argos Therapeutics Kidney Cancer Drugs Major Product Offerings
7.9.4 Argos Therapeutics Kidney Cancer Drugs Sales and Revenue in Global (2016-2021)
7.9.5 Argos Therapeutics Key News
7.10 ArQule
7.10.1 ArQule Corporate Summary
7.10.2 ArQule Business Overview
7.10.3 ArQule Kidney Cancer Drugs Major Product Offerings
7.10.4 ArQule Kidney Cancer Drugs Sales and Revenue in Global (2016-2021)
7.10.5 ArQule Key News
7.11 AVEO Pharmaceuticals
7.11.1 AVEO Pharmaceuticals Corporate Summary
7.11.2 AVEO Pharmaceuticals Kidney Cancer Drugs Business Overview
7.11.3 AVEO Pharmaceuticals Kidney Cancer Drugs Major Product Offerings
7.11.4 AVEO Pharmaceuticals Kidney Cancer Drugs Sales and Revenue in Global (2016-2021)
7.11.5 AVEO Pharmaceuticals Key News
7.12 Bionomics
7.12.1 Bionomics Corporate Summary
7.12.2 Bionomics Kidney Cancer Drugs Business Overview
7.12.3 Bionomics Kidney Cancer Drugs Major Product Offerings
7.12.4 Bionomics Kidney Cancer Drugs Sales and Revenue in Global (2016-2021)
7.12.5 Bionomics Key News
7.13 Bristol-Myers Squibb
7.13.1 Bristol-Myers Squibb Corporate Summary
7.13.2 Bristol-Myers Squibb Kidney Cancer Drugs Business Overview
7.13.3 Bristol-Myers Squibb Kidney Cancer Drugs Major Product Offerings
7.13.4 Bristol-Myers Squibb Kidney Cancer Drugs Sales and Revenue in Global (2016-2021)
7.13.5 Bristol-Myers Squibb Key News
7.14 Cerulean Pharma
7.14.1 Cerulean Pharma Corporate Summary
7.14.2 Cerulean Pharma Business Overview
7.14.3 Cerulean Pharma Kidney Cancer Drugs Major Product Offerings
7.14.4 Cerulean Pharma Kidney Cancer Drugs Sales and Revenue in Global (2016-2021)
7.14.5 Cerulean Pharma Key News
7.15 Exelixis
7.15.1 Exelixis Corporate Summary
7.15.2 Exelixis Business Overview
7.15.3 Exelixis Kidney Cancer Drugs Major Product Offerings
7.15.4 Exelixis Kidney Cancer Drugs Sales and Revenue in Global (2016-2021)
7.15.5 Exelixis Key News
7.16 Genentech
7.16.1 Genentech Corporate Summary
7.16.2 Genentech Business Overview
7.16.3 Genentech Kidney Cancer Drugs Major Product Offerings
7.16.4 Genentech Kidney Cancer Drugs Sales and Revenue in Global (2016-2021)
7.16.5 Genentech Key News
7.17 immatics biotechnologies
7.17.1 immatics biotechnologies Corporate Summary
7.17.2 immatics biotechnologies Business Overview
7.17.3 immatics biotechnologies Kidney Cancer Drugs Major Product Offerings
7.17.4 immatics biotechnologies Kidney Cancer Drugs Sales and Revenue in Global (2016-2021)
7.17.5 immatics biotechnologies Key News
7.18 Immunicum
7.18.1 Immunicum Corporate Summary
7.18.2 Immunicum Business Overview
7.18.3 Immunicum Kidney Cancer Drugs Major Product Offerings
7.18.4 Immunicum Kidney Cancer Drugs Sales and Revenue in Global (2016-2021)
7.18.5 Immunicum Key News
7.19 Ono Pharmaceutical
7.19.1 Ono Pharmaceutical Corporate Summary
7.19.2 Ono Pharmaceutical Business Overview
7.19.3 Ono Pharmaceutical Kidney Cancer Drugs Major Product Offerings
7.19.4 Ono Pharmaceutical Kidney Cancer Drugs Sales and Revenue in Global (2016-2021)
7.19.5 Ono Pharmaceutical Key News
7.20 Onyx Therapeutics
7.20.1 Onyx Therapeutics Corporate Summary
7.20.2 Onyx Therapeutics Business Overview
7.20.3 Onyx Therapeutics Kidney Cancer Drugs Major Product Offerings
7.20.4 Onyx Therapeutics Kidney Cancer Drugs Sales and Revenue in Global (2016-2021)
7.20.5 Onyx Therapeutics Key News
7.21 Oxford BioMedica
7.21.1 Oxford BioMedica Corporate Summary
7.21.2 Oxford BioMedica Business Overview
7.21.3 Oxford BioMedica Kidney Cancer Drugs Major Product Offerings
7.21.4 Oxford BioMedica Kidney Cancer Drugs Sales and Revenue in Global (2016-2021)
7.21.5 Oxford BioMedica Key News
7.22 Prometheus Laboratories
7.22.1 Prometheus Laboratories Corporate Summary
7.22.2 Prometheus Laboratories Business Overview
7.22.3 Prometheus Laboratories Kidney Cancer Drugs Major Product Offerings
7.22.4 Prometheus Laboratories Kidney Cancer Drugs Sales and Revenue in Global (2016-2021)
7.22.5 Prometheus Laboratories Key News
7.23 Seattle Genetics
7.23.1 Seattle Genetics Corporate Summary
7.23.2 Seattle Genetics Business Overview
7.23.3 Seattle Genetics Kidney Cancer Drugs Major Product Offerings
7.23.4 Seattle Genetics Kidney Cancer Drugs Sales and Revenue in Global (2016-2021)
7.23.5 Seattle Genetics Key News
7.24 Taiwan Liposome
7.24.1 Taiwan Liposome Corporate Summary
7.24.2 Taiwan Liposome Business Overview
7.24.3 Taiwan Liposome Kidney Cancer Drugs Major Product Offerings
7.24.4 Taiwan Liposome Kidney Cancer Drugs Sales and Revenue in Global (2016-2021)
7.24.5 Taiwan Liposome Key News
7.25 Tracon Pharmaceuticals
7.25.1 Tracon Pharmaceuticals Corporate Summary
7.25.2 Tracon Pharmaceuticals Business Overview
7.25.3 Tracon Pharmaceuticals Kidney Cancer Drugs Major Product Offerings
7.25.4 Tracon Pharmaceuticals Kidney Cancer Drugs Sales and Revenue in Global (2016-2021)
7.25.5 Tracon Pharmaceuticals Key News
7.26 Wilex
7.26.1 Wilex Corporate Summary
7.26.2 Wilex Business Overview
7.26.3 Wilex Kidney Cancer Drugs Major Product Offerings
7.26.4 Wilex Kidney Cancer Drugs Sales and Revenue in Global (2016-2021)
7.26.5 Wilex Key News
8 Global Kidney Cancer Drugs Production Capacity, Analysis
8.1 Global Kidney Cancer Drugs Production Capacity, 2016-2027
8.2 Kidney Cancer Drugs Production Capacity of Key Manufacturers in Global Market
8.3 Global Kidney Cancer Drugs Production by Region
9 Key Market Trends, Opportunity, Drivers and Restraints
9.1 Market Opportunities & Trends
9.2 Market Drivers
9.3 Market Restraints
10 Kidney Cancer Drugs Supply Chain Analysis
10.1 Kidney Cancer Drugs Industry Value Chain
10.2 Kidney Cancer Drugs Upstream Market
10.3 Kidney Cancer Drugs Downstream and Clients
10.4 Marketing Channels Analysis
10.4.1 Marketing Channels
10.4.2 Kidney Cancer Drugs Distributors and Sales Agents in Global
11 Conclusion
12 Appendix
12.1 Note
12.2 Examples of Clients
12.3 Disclaimer

...

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 世界の腎臓がん用薬剤市場予測2021-2027:血管新生阻害剤、mTOR阻害剤、モノクローナル抗体、サイトカイン免疫療法(IL-2)(Kidney Cancer Drugs Market - Global Outlook and Forecast 2021-2027)]についてメールでお問い合わせはこちらでお願いします。

◆H&Iグローバルリサーチのお客様(例)◆